Company profile

Dianthus Therapeutics, Inc. /DE/ insider acquisitions

Company CIK 0001690585 · Reported insider acquisitions and filing context.

Company filings at SEC ↗
DNTH · Nasdaq

These are company listings. A transaction is linked to a particular security only when the filing provides enough information.

Company activity summary

By transaction date, as of October 23, 2026.

7 days30 days90 daysOverlapping periods · securities and currencies kept separate

No records are loaded for this 7-day transaction window. This does not establish that no transactions occurred.

Known purchase value sums available amounts for non-derivative purchases only. Missing amounts are excluded. “Currency not specified” does not establish that the amounts share a currency. These summaries use all matching loaded records, while the timeline below covers only the current page.

Transaction timeline

Who reported an acquisition, and when the transaction occurred.

PurchaseStock awardGift receivedExercise / conversionConversionOther acquisition

7 dated transactions · 2 of 2 reporting owners shown. Select one owner to focus the chart.

View timeline as a table
Transaction dateCompany / securityReporting ownersAcquisition type
Dec 4, 2025Dianthus Therapeutics, Inc. /DE/Stock Option (Right to Buy)Savitz RyanExercise / conversion
Dec 4, 2025Dianthus Therapeutics, Inc. /DE/Common StockSavitz RyanExercise / conversion
Nov 14, 2025Dianthus Therapeutics, Inc. /DE/Common StockRandhawa SimratExercise / conversion
Nov 14, 2025Dianthus Therapeutics, Inc. /DE/Common StockRandhawa SimratExercise / conversion
Nov 14, 2025Dianthus Therapeutics, Inc. /DE/Common StockRandhawa SimratExercise / conversion
Nov 13, 2025Dianthus Therapeutics, Inc. /DE/Common StockRandhawa SimratExercise / conversion
Nov 13, 2025Dianthus Therapeutics, Inc. /DE/Common StockRandhawa SimratExercise / conversion

Only transactions on this page are shown. Date windows end on the latest transaction date in this sample. Joint filings may appear on more than one row. Sales are not included. Share-price charts use a separate data source.

Share price & reported acquisitions

Daily closing prices from a separate source. The date window above also filters prices; reporting-owner and transaction-type selections filter the markers.

Price history is not available

Market-price history is not connected yet.

DNTH · Currency not specified. A marker uses that day's closing price, not the reported transaction price. No price is substituted for a missing trading day.

Reported acquisitions

Filing-date filters apply to the list and timeline. The summary above uses transaction dates.

Reset
Reported insider acquisitions, ordered by filing date, newest first. Currency is shown only when reported.
Filed / transactedReporting ownersType / securityQuantityPrice / reference valueDetails
Trade:
Savitz RyanCFO & CBO
Exercise / conversionStock Option (Right to Buy)Derivative security · Code M20,0000Value: 0Currency not specifiedView ↗
Trade:
Savitz RyanCFO & CBO
Exercise / conversionCommon StockNon-derivative security · Code M20,0008.44Value: 168,800Currency not specifiedView ↗
Trade:
Randhawa SimratEVP, Head of R&D
Exercise / conversionCommon StockNon-derivative security · Code M31,25022.07Value: 689,687.5Currency not specifiedView ↗
Trade:
Randhawa SimratEVP, Head of R&D
Exercise / conversionCommon StockNon-derivative security · Code M37,49421.77Value: 816,244.38Currency not specifiedView ↗
Trade:
Randhawa SimratEVP, Head of R&D
Exercise / conversionCommon StockNon-derivative security · Code M40,28717.88Value: 720,331.56Currency not specifiedView ↗
Trade:
Randhawa SimratEVP, Head of R&D
Exercise / conversionCommon StockNon-derivative security · Code M3,52917.88Value: 63,098.52Currency not specifiedView ↗
Trade:
Randhawa SimratEVP, Head of R&D
Exercise / conversionCommon StockNon-derivative security · Code M83,9788.44Value: 708,774.32Currency not specifiedView ↗

Reporting owners are associated with a filing. Jointly reported amounts are not allocated to individual owners. Historical coverage is still being built. Read the methodology →